跳至主要内容
临床试验/NCT03049969
NCT03049969终止不适用

Cognitive Remediation Augmented With Transcranial Direct Current Stimulation (tDCS)

NYU Langone Health1 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2017年2月7日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
终止
入组人数
15
试验地点
1
主要终点
Number of Participants With Treatment Related Adverse Events

研究概览

简要总结

The proposed study will test the feasibility and tolerability of transcranial direct current stimulation (tDCS) added to a cognitive remediation program in n=100 adults. For 60 cognitive remediation sessions, participants will receive 20 minutes of active tDCS stimulation (up to 4.0 mA, dorsolateral prefrontal cortex or montage dependent on specific area of deficit) while they complete the cognitive training tasks.

详细描述

Transcranial Direct Current Stimulation (tDCS) is a novel, safe, well-tolerated, and low-cost treatment approach that may enhance the benefits of cognitive remediation. The application of tDCS is a relatively recent therapeutic development that utilizes low amplitude direct currents to induce changes in cortical excitability. To meet this study's objectives, investigators will focus specifically on working memory (WM) in both training and outcome. Limiting training to WM exercises will provide the opportunity to test proof of concept for the combined therapies within this shorter two-week time frame, and maximize the synergistic effect by engaging the same regions as targeted by the tDCS.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • At least 18 years of age
  • Clinician Referral for cognitive remediation.
  • Have undergone a neurological examination and neuropsychological examination as part of standard of care.
  • Has access to internet service at home compatible with the study laptop (Wi-Fi or ethernet cable)
  • Able to commit to the designated period of study training sessions with baseline and follow-up visits.
  • Able to understand the informed consent process and provide consent to participate in the study

排除标准

  • Visual, auditory and motor deficits that would prevent full ability to understand study instructions or operate the tDCS device or study laptop, as judged by treating clinician or study staff
  • Primary, uncontrolled psychiatric disorder that would influence ability to participate
  • Poorly controlled epilepsy
  • Medical device implanted in the head (such as Deep Brain Stimulator) or in the neck (such as a Vagus Nerve Stimulator)
  • Any skin disorder/sensitive skin (e.g., eczema, severe rashes), blisters, open wounds, burn including sunburns, cuts or irritation, or other skin defects which compromise the integrity of the skin at or near stimulation locations (where electrodes are placed)
  • Treatment for a communicable skin disorder currently or over the past 12 months
  • Other serious uncontrolled medical condition (e.g., cancer or acute myocardial infarction)
  • Wide Range Achievement Test-4th Edition (WRAT-4) Reading Recognition score <85*
  • Symbol Digit Modalities Test (SDMT) ≥3.0 SD below published norms*
  • Learned English language after 12 years of age
  • Pregnant or breastfeeding
  • In the case of the potential participant having either speech, motor or vision impairment secondary to their condition that will limit the completion of the SDMT and WRAT-4 screening measures the substitutions as mentioned above will be used.

研究组 & 干预措施

Cognitive Remediation

Experimental

For the 20 cognitive remediation sessions, eligible participants will receive 20 minutes of active tDCS stimulation (up to 2.0 mA, dorsolateral prefrontal cortex (dlPFC) motage) while they complete the cognitive training tasks. Once the participant has completed his/her 20 sessions a pre/post treatment assessment measures will be completed.

干预措施: tDCS stimulation (Device)

结局指标

主要结局

Number of Participants With Treatment Related Adverse Events

时间窗: End of treatment (up to 12 weeks)

Number of Participants Completing at Least 80% of the Targeted Number of Sessions.

时间窗: End of treatment (up to 12 weeks)

The protocol is designed to have a decision-tree series of checkpoints that must be met in order to proceed at each step

次要结局

  • Change in Visual Analogue Scale (VAS) for Pain Score(Baseline, end of treatment (up to 12 weeks))
  • Change in Negative Affect Score From the Positive and Negative Affect Scale (PANAS)(Baseline, end of treatment (up to 12 weeks))
  • Change in Positive Affect Score From the Positive and Negative Affect Scale (PANAS)(Baseline, end of treatment (up to 12 weeks))
  • Change in Symbol Digit Modalities Test (SDMT) Score(Baseline, end of treatment (up to 12 weeks))

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验